Owlstone technician using ReCIVA

Non invasive approaches to the earlier detection of disease

We have an active clinical diagnostics pipeline across oncology and inflammatory diseases.

Our large scale clinical studies

Our ambition is to save 100,000 lives and save healthcare providers $1.5 billion in costs. Owlstone Medical, together with its clinical partners, are actively engaged in clinical research across cancer, inflammation and infectious diseases. We are running clinical studies including the world's largest breath based clinical trial (LuCID) and have a strategic relationship with the CRUK funded Cambridge Centre to develop biomarkers for the early detection of cancer.

LuCID (Lung Cancer Indicator Detection) logo

LuCID - the early detection of lung cancer

Lung cancer is the most common cancer in the world with an estimated 1.8 million new cases and 1.6 million deaths each year. LuCID aims to develop a breath test for the early detection of lung cancer. LuCID is the world's largest breath-based clinical trial, recruiting up to 4,000 patients in 26 hospitals across Europe.

Learn more about LuCID
STRATA (STratification of Asthma Treatment by breath Analysis) logo

STRATA - stratifying asthma treatment

Asthma is the most common chronic airway disease in the world. We are working with clinical partners to develop breath-based biomarkers that move asthma treatment from trial and error to matching the right patient to the right treatment.

Learn more about Strata
InTERCEPT (Intestinal Tumour, Early Recognition Capacitating Early Preventive Treatment) logo

InTERCEPT - the early detection of colorectal cancer

Owlstone Medical’s technology for the early detection of colorectal cancer has the potential to save up to 75,000 lives per year in the EU alone. Our 1,400 patient study in collaboration with Warwick University is paving the way for earlier diagnosis. 

Learn more about Intercept
PAN Cancer trial logo

PAN - early detection of multiple cancers

Owlstone Medical is working in collaboration with leading cancer researchers at the Cancer Research UK (CRUK) Cambridge Centre on a large scale clinical study aiming to identify breath based biomarkers to improve the earlier detection and diagnosis of multiple different cancer types.

Learn more about PAN

Breath Biopsy: The Complete Guide, your introduction to breath biomarkers

DOWNLOAD FREE EBOOK
Breath Biopsy: The Complete Guide on a handheld tablet

More information about our clinical pipeline

If you want to know more about our clinical pipeline: protocols, publications and other research materials are available from our Resources section by using the keyword based search function.

Owlstone  world-leading team provides a range of premium services for non-invasive diagnostics

Our expert team can support every step of your breath biomarker research from study design to data analysis

View our services